✨ Health Notices




2 MAY 2013 NEW ZEALAND GAZETTE, No. 48 1455

manager for the board of trustees of Hamilton Junior High School.
All functions, powers and duties of the board to manage financial operations (whether statutory or otherwise) are to be vested in a limited statutory manager.

This notice takes effect on the day of publication.
Dated at Wellington this 30th day of April 2013.

HON HEKIA PARATA, Minister of Education.

go2570


Health

Medicines Act 1981

Renewal of Provisional Consent to the Distribution of a Medicine

Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:

Schedule

Product: RiaSTAP
Active Ingredient: Fibrinogen 900mg – 1300mg
Dosage Form: Powder for injection
New Zealand Sponsor: bioCSL (NZ) Limited
Manufacturer: CSL Behring GmbH, Marburg, Germany

Note: This renewed consent is valid for two years from 12 May 2013.

Dated this 24th day of April 2013.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go2492

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Arrow - Dortim
Active Ingredients: Dorzolamide hydrochloride 22.26mg/mL equivalent to Dorzolamide 20mg/mL
Timolol maleate 6.83mg/mL equivalent to Timolol 5mg/mL
Dosage Form: Eye drops, solution
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: FDC Limited, District Aurangabad, India

Product: Suxamethonium Chloride
Active Ingredient: Suxamethonium chloride dihydrate 5%w/v
Dosage Form: Solution for injection
New Zealand Sponsor: Max Health Limited
Manufacturer: Martindale Pharmaceuticals, Essex, United Kingdom

Dated this 24th day of April 2013.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go2490

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:

Schedule

Product: Afinitor
Active Ingredient: Everolimus 5mg
Dosage Form: Tablet
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturers: Novartis Pharma AG, Basel, Switzerland
Novartis Pharma Stein AG, Stein, Switzerland



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2013, No 48





✨ LLM interpretation of page content

πŸŽ“ Notice of Direction to Appoint a Limited Statutory Manager for the Board of Trustees of Hamilton Junior High School (continued from previous page)

πŸŽ“ Education, Culture & Science
30 April 2013
Education Act, Hamilton Junior High School, Limited Statutory Manager
  • HON HEKIA PARATA, Minister of Education

πŸ₯ Renewal of Provisional Consent to the Distribution of a Medicine

πŸ₯ Health & Social Welfare
24 April 2013
Medicines Act, RiaSTAP, Fibrinogen, bioCSL (NZ) Limited
  • DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
24 April 2013
Medicines Act, Arrow - Dortim, Suxamethonium Chloride, Arrow Pharmaceuticals (NZ) Limited, Max Health Limited
  • DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
24 April 2013
Medicines Act, Afinitor, Everolimus, Novartis New Zealand Limited
  • DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health